APO-PERINDOPRIL ARGININE perindopril arginine 5 mg tablet blister pack Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

apo-perindopril arginine perindopril arginine 5 mg tablet blister pack

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; isomalt; magnesium stearate; hypromellose; brilliant blue fcf aluminium lake; titanium dioxide; hyprolose; colloidal anhydrous silica; macrogol 8000 - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

APO-PERINDOPRIL ARGININE perindopril arginine 10 mg tablet blister pack Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

apo-perindopril arginine perindopril arginine 10 mg tablet blister pack

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 10 mg - tablet, film coated - excipient ingredients: iron oxide yellow; colloidal anhydrous silica; hypromellose; isomalt; titanium dioxide; macrogol 8000; magnesium stearate; brilliant blue fcf aluminium lake; hyprolose - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

APO-PERINDOPRIL perindopril erbumine 8mg tablets blister pack Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

apo-perindopril perindopril erbumine 8mg tablets blister pack

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: lactose; magnesium stearate - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril have not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of nonfatal myocardial infarction or cardiac arrest.

APO-PERINDOPRIL perindopril erbumine 4mg tablets blister pack Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

apo-perindopril perindopril erbumine 4mg tablets blister pack

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: lactose; magnesium stearate - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril have not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of nonfatal myocardial infarction or cardiac arrest.

APO-PERINDOPRIL perindopril erbumine 2mg tablets blister pack Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

apo-perindopril perindopril erbumine 2mg tablets blister pack

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril have not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of nonfatal myocardial infarction or cardiac arrest.

PERINDOPRIL ERBUMINE tablet Spojené státy - angličtina - NLM (National Library of Medicine)

perindopril erbumine tablet

lannett company, inc. - perindopril erbumine (unii: 1964x464oj) (perindoprilat - unii:2uv6znq92k) - perindopril erbumine 4 mg - perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. perindopril erbumine tablets are contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ace inhibitor. perindopril erbumine tablets are also contraindicated in patients with hereditary or idiopathic angioedema. do not co-administer aliskiren with perindopril erbumine in patients with diabetes [see drug interactions (7.8)]. pregnancy category d  [see boxed warning and warn

PERINDOPRIL ERBUMINE tablet Spojené státy - angličtina - NLM (National Library of Medicine)

perindopril erbumine tablet

marlex pharmaceuticals inc - perindopril erbumine (unii: 1964x464oj) (perindoprilat - unii:2uv6znq92k) - perindopril erbumine 4 mg - perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. perindopril erbumine tablets are contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ace inhibitor. perindopril erbumine tablets are also contraindicated in patients with hereditary or idiopathic angioedema. do not co-administer aliskiren with perindopril erbumine in patients with diabetes [see drug interactions ( 7.8 )] . pregnancy category d  [see boxed warning and

PERINDOPRIL GENERICHEALTH perindopril erbumine 8mg tablet blister pack Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

perindopril generichealth perindopril erbumine 8mg tablet blister pack

lupin australia pty limited - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; silica dimethyl silylate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

PERINDOPRIL GENERICHEALTH perindopril erbumine 4mg tablet blister pack Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

perindopril generichealth perindopril erbumine 4mg tablet blister pack

lupin australia pty limited - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: silica dimethyl silylate; lactose monohydrate; microcrystalline cellulose; magnesium stearate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

PERINDOPRIL GENERICHEALTH perindopril erbumine 2mg tablet blister pack Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

perindopril generichealth perindopril erbumine 2mg tablet blister pack

lupin australia pty limited - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: silica dimethyl silylate; magnesium stearate; microcrystalline cellulose; lactose monohydrate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.